Does Ozempic Cause Thyroid Cancer? What the Research Actually Shows

Every GLP-1 medication carries a black box warning about thyroid cancer. That warning is alarming and deserves an honest explanation — not the "consult your doctor" dismissal that most articles offer. Here is what the data actually says.

What the Black Box Warning Says

GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity) all carry an FDA black box warning stating that these drugs caused thyroid C-cell tumors in rodent studies and that their relevance to humans is unknown. The medications are contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

The Rodent Study: What It Actually Found

The thyroid cancer concern originates from pre-approval animal studies conducted with liraglutide (Victoza) and subsequently confirmed with semaglutide. Rodents given GLP-1 agonists at high doses developed C-cell adenomas and carcinomas in the thyroid — specifically medullary thyroid carcinoma (MTC), which originates in parafollicular C-cells rather than in the thyroid follicular cells where the more common papillary and follicular thyroid cancers originate.

Three critical context points about the animal studies:

1. Rodent thyroid C-cells express GLP-1 receptors at much higher density than human C-cells. Rodents are known to be particularly sensitive to this mechanism. This species-specific difference makes direct extrapolation to humans problematic.
2. Doses used in animal studies were much higher than clinical human doses. In the liraglutide studies, rats received doses 8–60 times the maximum human dose over their 2-year lifespan.
3. The tumors took 2 years to develop in rodents — the equivalent of a much longer exposure period relative to typical human GLP-1 use.

What Human Data Shows

Multiple large epidemiological studies have examined GLP-1 use and thyroid cancer risk in humans:

• A 2023 JAMA Internal Medicine study (over 145,000 GLP-1 users vs. controls) found a statistically significant association between GLP-1 use and thyroid cancer, but the absolute risk increase was small and the study had limitations including short follow-up time
• The Novo Nordisk-sponsored LEADER trial (cardiovascular outcomes trial for liraglutide, 9,340 patients, 3.8 year follow-up) did not show a significant increase in thyroid malignancies
• The SELECT trial (semaglutide, 17,604 patients) similarly did not report a confirmed signal for MTC

The FDA continues to require the black box warning because the animal data creates a theoretical concern that cannot be definitively ruled out in humans without very long-term follow-up data — which doesn't exist yet for drugs that have been in wide use for only 5–10 years.

The Absolute vs. Relative Risk Reality

Medullary thyroid carcinoma is rare regardless of GLP-1 use. MTC accounts for approximately 3–5% of all thyroid cancers, and thyroid cancer overall affects roughly 0.03% of the US population per year. Even if GLP-1 medications doubled the relative risk of MTC — which has not been established in humans — the absolute risk increase would still be very small.

For perspective: the cardiovascular benefits of GLP-1 medications in high-risk patients (reduced major cardiac events, reduced heart failure hospitalizations) represent a far larger and better-established benefit than the theoretical thyroid risk.

Who Should Actually Be Concerned

The black box warning is practically relevant for a specific population: people with a personal or family history of medullary thyroid carcinoma or MEN 2. For these individuals, GLP-1 medications are genuinely contraindicated and alternatives should be used.

For the general population without these risk factors, the current human evidence does not support an elevated real-world risk of clinically significant thyroid cancer. The warning reflects scientific caution, not a known human effect.

Monitoring Recommendations

If you are using a GLP-1 medication, there is no specific thyroid cancer screening protocol recommended beyond standard care. However:

• Tell your prescriber if you develop a new neck lump, difficulty swallowing, hoarseness, or enlarged lymph nodes in the neck — these warrant evaluation
• Ensure your physician knows your family history before prescribing
• Routine thyroid function tests (TSH) are not affected by GLP-1 use and don't screen for MTC

Frequently Asked Questions